Albany, NY -- (SBWIRE) -- 05/11/2016 -- Medical experts have recognized sedentary lifestyles and unhealthy food choices, which lead to conditions such as coronary artery diseases, cardiomyopathy, as critical reasons for heart failure. While the first steps of treatment range from tight control over diet and medications to lifestyle, in the event of the progression of the condition, more advanced treatment options need to be administered.

In a new report by Transparency Market Research, the progression of the global congestive heart failure devices market is presented for a forecast period from 2012 to 2018. According to the report's findings, the global congestive failure treatment devices market will display double-digit growth rate in the coming years. A complete analysis of vital market indicators, technological innovations, and the competitive structure of this market is presented in the report, titled "Congestive Heart Failure Treatment Devices Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 – 2018." The report studies this market across the regional segments of North America, Europe, Asia Pacific, and Rest of the World for the aforementioned forecast period.

Congestive heart failure (CHF) happens when the heart muscles do not pump blood as they should to meet the metabolic needs of tissue and body organs. The increasing incidence of heart failures worldwide, an increasing geriatric population pool, greater awareness about CHF, and changing lifestyles are driving the growth of the congestive heart failure treatment devices market, says the report.

The U.S. and European markets hold immense growth potential for congestive heart failure treatment devices on account of the increasing incidence of congestive heart failures in these regions. This is evident from the increasing valuation of the American market for congestive heart failure treatment devices over the past few years.

In absolute numbers, the American market for congestive heart failure treatment devices stood at US$1.6 bn in 2010 and will be valued at US$3.2 bn by the end of 2016. Likewise, the Europe market is expected to reach a valuation of US$1.5 bn by the end of 2016. The emerging markets of Asia Pacific and Latin America will display significant growth due to reforms aimed at modernizing healthcare practices, the changing demographics, increasing income levels, and availability of newer treatments for congestive heart failure.